Literature DB >> 13678670

Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes.

M A Kurt1, D C Davies, M Kidd, K Duff, D R Howlett.   

Abstract

Senile plaques composed mainly of beta-amyloid (Abeta) and neurofibrillary tangles principally composed of hyperphosphorylated tau are the major pathological features of Alzheimer's disease (AD). Despite the fact that increased expression of amyloid precursor protein (APP) and presenilin-1 (PS1) transgenes in mice lead to increased Abeta deposition in plaquelike structures in the brain, little is known about the nature and distribution of tau in these mice. Therefore the relationship between Abeta and hyperphosphorylated tau was investigated in mice carrying mutant APP and mutant PS1 transgenes using both light (LM) and electron microscopy (EM) with immunocytochemistry. LM immunocytochemistry revealed cerebral Abeta deposits to be present from 8 weeks of age, whereas hyperphosphorylated tau was not detected until 24 weeks of age, when it appeared as punctate deposits in close association with the Abeta deposits in the cortex and hippocampus. However, dystrophic neurites were not as heavily immunolabeled as they are in AD brain. EM revealed that aggregations of straight filaments (10-12 nm wide) were present in some cellular processes at the periphery of Abeta plaques in 8-month-old APP/PS1 mice. In one such mouse, single filaments and paired filaments showing a helical configuration (50-55 nm half-period, 25 nm max. width) were present in a dark, atrophic hippocampal neuron. Immunogold labeling of APP/PS1 mouse brain revealed hyperphosphorylated tau epitopes in some dystrophic neurites from 24 weeks of age that were similar to those present in AD. These results suggest that hyperphosphorylated tau appears in APP/PS1 mouse brain after the onset of Abeta deposition and although it is associated with Abeta deposits, its distribution is not identical to that in AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13678670     DOI: 10.1016/s0969-9961(03)00084-6

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  33 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

2.  Impaired neurogenesis is an early event in the etiology of familial Alzheimer's disease in transgenic mice.

Authors:  Michael Demars; Yuan-Shih Hu; Archana Gadadhar; Orly Lazarov
Journal:  J Neurosci Res       Date:  2010-08-01       Impact factor: 4.164

3.  Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease.

Authors:  Bin Liang; Bao-Yu Duan; Xiu-Ping Zhou; Jia-Xin Gong; Zhen-Ge Luo
Journal:  J Biol Chem       Date:  2010-07-01       Impact factor: 5.157

4.  Epigallocatechin-3-gallate Alleviates Cognitive Deficits in APP/PS1 Mice.

Authors:  Jian Bao; Wei Liu; Hong-Yan Zhou; Yu-Ran Gui; You-Hua Yang; Meng-Juan Wu; Yi-Fan Xiao; Jin-Ting Shang; Gui-Feng Long; Xi-Ji Shu
Journal:  Curr Med Sci       Date:  2020-03-13

5.  Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease.

Authors:  Chunyan Zhu; Bing Xu; Xiaohong Sun; Qiwen Zhu; Yi Sui
Journal:  Mol Neurobiol       Date:  2016-11-23       Impact factor: 5.590

6.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

7.  Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.

Authors:  Yun Ding; Aimin Qiao; Ziqing Wang; J Shawn Goodwin; Eun-Sook Lee; Michelle L Block; Matthew Allsbrook; Michael P McDonald; Guo-Huang Fan
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

8.  Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.

Authors:  C Vergara; L Ordóñez-Gutiérrez; F Wandosell; I Ferrer; J A del Río; R Gavín
Journal:  Mol Neurobiol       Date:  2014-06-26       Impact factor: 5.590

Review 9.  The value of incomplete mouse models of Alzheimer's disease.

Authors:  Rebecca Radde; Cecilia Duma; Michel Goedert; Mathias Jucker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

10.  Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2.

Authors:  Ruiben Feng; Huimin Wang; Jianlin Wang; David Shrom; Xuemei Zeng; Joe Z Tsien
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.